KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Common Equity (2016 - 2025)

Pacira BioSciences (PCRX) has 16 years of Common Equity data on record, last reported at $693.1 million in Q4 2025.

  • For Q4 2025, Common Equity fell 10.95% year-over-year to $693.1 million; the TTM value through Dec 2025 reached $693.1 million, down 10.95%, while the annual FY2025 figure was $693.1 million, 10.95% down from the prior year.
  • Common Equity reached $693.1 million in Q4 2025 per PCRX's latest filing, down from $727.2 million in the prior quarter.
  • Across five years, Common Equity topped out at $892.2 million in Q1 2024 and bottomed at $650.8 million in Q1 2021.
  • Average Common Equity over 5 years is $767.6 million, with a median of $762.9 million recorded in 2023.
  • Peak YoY movement for Common Equity: skyrocketed 77.04% in 2021, then fell 13.82% in 2025.
  • A 5-year view of Common Equity shows it stood at $730.4 million in 2021, then rose by 6.11% to $775.0 million in 2022, then increased by 12.27% to $870.1 million in 2023, then fell by 10.55% to $778.3 million in 2024, then decreased by 10.95% to $693.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $693.1 million in Q4 2025, $727.2 million in Q3 2025, and $757.8 million in Q2 2025.